Blood test may predict liver cancer comeback and immunotherapy success
NCT ID NCT07350824
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a blood test that detects tiny bits of tumor DNA (called minimal residual disease) can predict if liver cancer will come back after surgery. Researchers will test 276 patients before and after surgery to see if the test can also identify who might benefit from additional immunotherapy. The goal is to find a better way to monitor patients and guide treatment decisions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Division of Hepato-Pancreato-Biliary Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Two punch slow recurrent brain cancer?
- Can a targeted pill slow brain tumor growth after surgery?
- A made-to-order DNA vaccine takes aim at liver cancer's return
- DNA clues may reveal which esophageal cancers will return soon after surgery
- Simple blood test aims to catch liver cancer before It's too late
- Blood test may end painful bone marrow biopsies for myeloma patients